Lake Street initiated coverage of AxoGen (AXGN) with a Buy rating and $30 price target Axogen’s portfolio of nerve repair products is clinically supported with “robust market verification” and the renewed growth strategy being implemented by newly appointed CEO Mike Dale focuses on maturing the company to “entrench itself as the standard of care” in its $5.6B nerve repair total addressable market, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
- AxoGen’s Strategic Growth Potential and Market Expansion: Analyst Recommends Buy Rating
- AxoGen’s Strategic Growth and Market Positioning: Buy Rating Affirmed by Caitlin Cronin
- AxoGen’s Strategic Market Positioning and Anticipated BLA Approval Drive Buy Rating
- AxoGen Unveils Strategic Priorities for 2025-2028
- AxoGen Reports Strong Growth and Positive Outlook